Related Experiment Video
Updated: Jun 10, 2026
09:06
Isolation of Stem-like Cells from 3-Dimensional Spheroid Cultures
Published on: December 13, 2019
P504S expressing circulating prostate cells as a marker for prostate cancer
Nigel P Murray1, Gloria M Calaf, Leonardo Badinez
1Subdivisión de Hematologóa, Hospital de Carabineros, Nuñoa, Santiago, Chile. nigelpetermurray@gmail.com
Oncology Reports
|July 29, 2010
Summary
Detecting circulating prostate cells using markers like CD82 may aid prostate cancer screening. This method identified prostate cells in 16.6% of men, offering a potential complementary test for elevated prostate specific antigen (PSA) levels.
Area of Science:
- Oncology
- Biomarker Discovery
- Urology
Background:
- Prostate cancer is a leading cause of cancer death in men.
- Serum prostate specific antigen (PSA) is the primary screening biomarker.
- Current screening methods have limitations.
Purpose of the Study:
- To develop a system for detecting circulating prostate cells in men without a prostate cancer diagnosis.
- To investigate the co-expression of CD82, HER-2, and matrix metalloproteinase 2 (MMP-2) in these cells.
- To correlate circulating prostate cell detection with age, PSA levels, and prostate biopsy results.
Main Methods:
- Mononuclear cells were isolated from blood via differential centrifugation.
- Standard immunocytochemical methods were used to identify prostate cells.
- Co-expression of CD82, HER-2, and MMP-2 was analyzed.
Main Results:
- Circulating prostate cells were detected in 16.6% of 409 screened men.
- MMP-2 and HER-2 were expressed in 100% and 14.3% of positive cases, respectively, irrespective of age or PSA.
- CD82 expression correlated with older age and low-grade tumors.
Conclusions:
- Circulating prostate cell detection using specific markers shows promise as a complementary screening tool.
- CD82 expression may indicate a link to specific tumor characteristics.
- Further research into circulating prostate cells could improve prostate cancer detection strategies.
